MX2021001254A - Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. - Google Patents

Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.

Info

Publication number
MX2021001254A
MX2021001254A MX2021001254A MX2021001254A MX2021001254A MX 2021001254 A MX2021001254 A MX 2021001254A MX 2021001254 A MX2021001254 A MX 2021001254A MX 2021001254 A MX2021001254 A MX 2021001254A MX 2021001254 A MX2021001254 A MX 2021001254A
Authority
MX
Mexico
Prior art keywords
mica
antibodies
methods
shedding
block
Prior art date
Application number
MX2021001254A
Other languages
English (en)
Inventor
Xin Du
Neil Gibson
Justin Chapman
Original Assignee
Cullinan Mica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullinan Mica Corp filed Critical Cullinan Mica Corp
Publication of MX2021001254A publication Critical patent/MX2021001254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En este documento se proporcionan anticuerpos que se unen específicamente a MICA/B que tienen dominios de cadena pesada, cadena ligera, cadena pesada variable (VH), dominios de cadena ligera variable (VL) y regiones determinantes de complementariedad (CDR) descritos en este documento, así como métodos y usos de los mismos.
MX2021001254A 2018-07-31 2019-07-30 Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. MX2021001254A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712608P 2018-07-31 2018-07-31
PCT/US2019/044234 WO2020028428A2 (en) 2018-07-31 2019-07-30 Anti-mica/b antibodies that block mica/b shedding and methods of use

Publications (1)

Publication Number Publication Date
MX2021001254A true MX2021001254A (es) 2021-05-12

Family

ID=69231308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001254A MX2021001254A (es) 2018-07-31 2019-07-30 Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.

Country Status (13)

Country Link
US (1) US20210253711A1 (es)
EP (1) EP3830128A4 (es)
JP (2) JP7370376B2 (es)
KR (1) KR20210071947A (es)
CN (1) CN113056484A (es)
AU (1) AU2019312565A1 (es)
BR (1) BR112021001808A2 (es)
CA (1) CA3108022A1 (es)
IL (1) IL280487A (es)
MX (1) MX2021001254A (es)
PH (1) PH12021550232A1 (es)
SG (1) SG11202100981TA (es)
WO (1) WO2020028428A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115611982B (zh) * 2021-07-14 2024-05-10 浙江大学 一种抗人MICA/Bα3区的单克隆抗体及其应用
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
WO2024026414A1 (en) * 2022-07-28 2024-02-01 Cullinan Mica Corporation Anti-mica/b antibodies with enhanced effector function and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054816A2 (en) * 2005-11-14 2007-05-18 Bioren, Inc. Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening
AU2013218017B2 (en) * 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
KR20150100881A (ko) * 2012-12-24 2015-09-02 애브비 인코포레이티드 프롤락틴 수용체 결합 단백질 및 이의 용도
EP2970490A4 (en) * 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
AU2017235274A1 (en) * 2016-03-15 2018-08-16 Innate Pharma Anti-mica antibodies
US11066471B2 (en) * 2016-10-19 2021-07-20 Novelogics Biotechnology Inc. Antibodies to MICA and MICB proteins
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法

Also Published As

Publication number Publication date
AU2019312565A1 (en) 2021-03-11
IL280487A (en) 2021-03-25
JP2024009997A (ja) 2024-01-23
KR20210071947A (ko) 2021-06-16
US20210253711A1 (en) 2021-08-19
JP2021532774A (ja) 2021-12-02
JP7370376B2 (ja) 2023-10-27
WO2020028428A3 (en) 2020-05-07
EP3830128A2 (en) 2021-06-09
SG11202100981TA (en) 2021-02-25
EP3830128A4 (en) 2022-08-17
CN113056484A (zh) 2021-06-29
CA3108022A1 (en) 2020-02-06
PH12021550232A1 (en) 2021-12-06
BR112021001808A2 (pt) 2021-08-03
WO2020028428A2 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
PH12021550232A1 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
MX2019013387A (es) Dominio de union a antigeno.
MX2016003593A (es) Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
TR201909647T4 (tr) Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car).
MX2019011910A (es) Anticuerpos biespecificos de union especifica a pd1 y lag3.
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
MA39266A (fr) Anticorps bispécifiques anti cd3epsilon et bcma
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
NZ728749A (en) Anti-pd-l1 antibodies
MX360707B (es) Receptor antigénico quimérico.
NZ626269A (en) Anti-phf-tau antibodies and their uses
PE20211887A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
MX2016008794A (es) Secuencias de anticuerpos especificos para e. coli.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2019011585A (es) Anticuerpos miltiespecificos estables.
CR20220650A (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
MX2022015114A (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso.